Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shanta Salzer"'
Autor:
Fang Hu, Brian T. Hess, Sarah Hogan, Nina D. Wagner-Johnston, Lindsey Hendrickson, Shanta Salzer, Leandro Cerchietti, Robin Klingenberg, Elizabeth G. Hill, Lacey Finch, Anshu Giri
Publikováno v:
Blood. 138:3567-3567
Background A significant portion of diffuse large B-cell lymphoma (DLBCL) patients (35-40%) relapse or are refractory to frontline chemotherapy. The standard of care for relapsed/refractory (R/R) DLBCL patients has been salvage chemotherapy followed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::523dd4073fcbd95fd057c54ba75357a7
https://doi.org/10.1182/blood-2021-145493
https://doi.org/10.1182/blood-2021-145493
Autor:
Carol A. Sherman, Mario L. Meyer, Steven Dunder, Andrew S. Kraft, Alberto J. Montero, Uzair B. Chaudhary, Mark R. Green, John Hayslip, Shanta Salzer
Publikováno v:
BMC Cancer, Vol 7, Iss 1, p 221 (2007)
BMC Cancer
BMC Cancer
Background COX-2 inhibitors, such as celecoxib, and ubiquitin-proteasome pathway inhibitors, such as bortezomib, can down-regulate NF-κB, a transcription factor implicated in tumor growth. The objective of this study was to determine the maximum tol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0931f544dbff12bee5d3b291ab18d93
http://www.biomedcentral.com/1471-2407/7/221
http://www.biomedcentral.com/1471-2407/7/221
Autor:
Rachel Whirley, Robert K. Stuart, Joseph Stephenson, Suzanne Fanning, Lawrence B. Afrin, Tricia A. Bentz, Shanta Salzer, Carlyn Sander, Luciano J. Costa
Publikováno v:
Blood. 120:3933-3933
Abstract 3933 Background Ofatumumab is a novel fully humanized anti-CD20 monoclonal antibody with antigenic target distinct from rituximab and enhanced antibody dependent cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) with single age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::339618d2cd36755ad5e1e470b25df779
https://doi.org/10.1182/blood.v120.21.3933.3933
https://doi.org/10.1182/blood.v120.21.3933.3933
Autor:
Uzair B. Chaudhary, Shanta Salzer, Alberto J. Montero, S. Dunder, Mark R. Green, Mario L. Meyer, Andrew S. Kraft, F. Brescia
Publikováno v:
Journal of Clinical Oncology. 24:13051-13051
13051 Background: The ubiquitin-proteosome pathway plays an important role in cell cycle regulation, neoplastic growth, and metastasis. Nuclear factor-kB (NF-kB) is a key transcription factor in cancer, primarily regulated by proteosome-mediated degr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::786ded95a40b28ee4e67ebbf08220e07
https://doi.org/10.1200/jco.2006.24.18_suppl.13051
https://doi.org/10.1200/jco.2006.24.18_suppl.13051